Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Transplant ; 16(6): 651-7, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22738273

ABSTRACT

RTx is best treatment for children with ESRD. Data scarcity on DDRTx outcome in children prompted us to review our experience. This study was undertaken to evaluate patient/graft survival, function vis-a-vis SCr, rejection episodes, and mortality in DDRTx performed in 37 children between 1998 and 2011. The most common recipient diseases leading to ESRD were congenital anomalies of kidney and urinary tract (48.6%) and chronic glomerulonephritis (18.9%). Mean recipient age was 13.8 ± 3.1 yr; 67.5% (n = 25) were men. Mean donor age was 38.8 ± 18.6 yr; 48.5% (n = 18) were men. Mean dialysis duration pre-transplantation was 15.5 ± 3.5 months. All recipients received r-ATG, and triple immunosuppression. Over a mean follow-up of 3.93 ± 3.5 yr, patient and graft survival rates were 72.9% (n = 27) and 83.7% (n = 31), respectively, with a mean SCr of 1.1 mg/dL; 21.6% (n = 8) of patients had acute rejection episodes; 24.3% (n = 9) of patients had DGF. A total of 27% (n = 10) patients died, mainly owing to infections (n = 6) and cardiovascular disease (n = 3). DDRTx is a viable option for children and achieves acceptable graft function with patient/graft survival over long-term follow-up, encouraging use of this approach.


Subject(s)
Kidney Failure, Chronic/therapy , Kidney Transplantation/methods , Adolescent , Adult , Child , Child, Preschool , Developing Countries , Female , Graft Survival , Humans , India , Kidney Failure, Chronic/mortality , Male , Middle Aged , Pediatrics , Reproducibility of Results , Time Factors , Tissue Donors , Tissue and Organ Procurement , Treatment Outcome
2.
Saudi J Kidney Dis Transpl ; 23(1): 37-43, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22237216

ABSTRACT

Methanol is a cheap and potent adulterant of illicit liquors. Hemodialysis (HD) is the best method to rapidly remove both toxic acid metabolites and parent alcohols, and it plays a fundamental role in treating severely poisoned patients. This retrospective study was carried out on 91 patients with detectable serum methanol levels who underwent HD. Because toxic alcohol levels were not immediately available, the initial diagnosis and treatment was based on clinical history with evidence of toxic alcohol intake, presence of high anion metabolic acidosis and/or end organ damage. Patients received bicarbonate, ethanol, according to clinical features and blood gases. Patients underwent HD in the setting of known methanol ingestion with high anion gap metabolic acidosis, or evidence of end-organ damage, regardless of methanol level. HD prescription included large surface area dialyzer (≥ 1.5 m²), blood flow rate of 250-350 mL/min and dialysate flow rate of 500 mL/min for 4-6 h. Between 9 and 11 July 2009, 91 males with mean age 40 ± 8.5 years underwent HD, and 13 patients required a second HD session. Patients consumed 100-500 mL illicit liquors, and symptoms appeared six and 60 h later. Clinical features were gastro-intestinal symptoms (83.5%), visual disturbances (60.4%), central nervous system symptoms (59.3%) and dyspnea (43.9%). Before HD, mean pH was 7.11 ± 0.04 (range 6.70- 7.33) and mean bicarbonate levels were 8.5 ± 4.9 mmol/L (range 2-18). Three patients died due to methanol intoxication. Mortality was associated with severe metabolic acidosis (pH ≤ 6.90), ventilator requirement and coma/seizure on admission (P < 0.001). Timely HD, bicarbonate, ethanol and supportive therapy can be life-saving in methanol intoxication.


Subject(s)
Alcoholic Beverages/poisoning , Methanol/poisoning , Renal Dialysis , Acidosis/chemically induced , Acidosis/therapy , Adult , Bicarbonates/administration & dosage , Chi-Square Distribution , Coma/chemically induced , Coma/therapy , Combined Modality Therapy , Ethanol/administration & dosage , Humans , Hydrogen-Ion Concentration , India , Male , Methanol/blood , Middle Aged , Poisoning/etiology , Poisoning/mortality , Poisoning/therapy , Respiration, Artificial , Retrospective Studies , Seizures/chemically induced , Seizures/therapy , Time Factors , Treatment Outcome
3.
Int Urol Nephrol ; 44(1): 269-74, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21805084

ABSTRACT

BACKGROUND: Type 2 diabetes mellitus (DM) is the commonest cause of end-stage renal disease (ESRD) worldwide. Renal transplantation (RTx) is the best therapeutic modality for such patients. First-degree relatives of patients with type 2 DM have high risk of diabetes/pre-diabetes. Parents are often too old to be suitable donors, and siblings/children/spouse are either not suitable/acceptable or do not come forward for organ donation. This leaves deceased donation (DD) as only suitable donors. Data scarcity on DDRTx outcome in diabetic nephropathy (DN) prompted us to review our experience. This retrospective single-center 10-year study was undertaken to evaluate patient/graft survival, graft function, rejection episodes, and mortality in these patients. MATERIALS AND METHODS: Between January 2001 and March 2011, thirty-five DN-ESRD patients underwent DDRTx in our center following cardiac fitness assessment of recipients. All patients received single-dose rabbit-anti-thymocyte globulin for induction and steroids, calcineurin inhibitor, and mycophenolate mofetil/azathioprine for maintenance immunosuppression. Mean recipient age was 49.66 ± 6.76 years, and 25 were men. Mean donor age was 50 ± 16.45 years, 23 were men. RESULTS: Over a mean follow-up of 2.28 ± 2.59 years, patient and graft survival rates were 68.5% and 88.5%, respectively, with mean SCr of 1.9 ± 0.62 mg/dl. Delayed graft function was observed in 34.3% patients, and 25.7% had biopsy-proven acute rejection; 31.5% patients died, mainly because of infections (22.8%), coronary artery disease (2.86%), and cerebrovascular events (5.7%). CONCLUSION: DDRTx in patients with DN has acceptable graft function and patient/graft survival over 10-year follow-up in our center and, therefore, we believe it should be encouraged.


Subject(s)
Diabetic Nephropathies/surgery , Graft Survival , Kidney Failure, Chronic/surgery , Kidney Transplantation/immunology , Adult , Aged , Antilymphocyte Serum/therapeutic use , Azathioprine/therapeutic use , Cadaver , Calcineurin Inhibitors , Creatinine/blood , Delayed Graft Function/blood , Developing Countries , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/etiology , Female , Graft Rejection/pathology , Humans , Immunosuppression Therapy/adverse effects , Immunosuppressive Agents/therapeutic use , India , Kidney Failure, Chronic/etiology , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Retrospective Studies , Steroids/therapeutic use , Treatment Outcome
4.
J Assoc Physicians India ; 60: 24-7, 2012 Jul.
Article in English | MEDLINE | ID: mdl-23405537

ABSTRACT

BACKGROUND: Deceased donor organ shortage has made living donors (LD) major source for renal transplantation (RTx) in India. Spouses represent an important source of allograft. We carried out a retrospective study of spousal RTx vs. other LDRTx to compare long-term results. METHODS: This retrospective single-center study was undertaken to evaluate demographic, patient survival, graft survival, function vis-à-vis serum creatinine (SCr) and rejection episodes in 1523 living donor renal allograft recipients from 1998 to 2009. It included spouse donors (n=337) (group 1), living related donors (LRD) (n=969) (group 2), and living unrelated donors (LUD) (n=217) (group 3). RESULTS: Mean recipient age (years +/- SD)) was 41.48 +/- 8.87, 30.49 +/- 10.61, and 37.13 +/- 13.25, respectively for the three groups who were followed for 4.47 +/- 3.03, 4.47 +/- 3.0 and 5.15 +/- 3.28 years respectively. Female donors were 92.6%, 66.4%, and 41%, mean HLA match was 1.15 +/- 0.93, 3 +/- 1.05 and 1.30 +/- 1.08 respectively. One, 5 and 12 year graft survivals among group 1 were 91.39%, 75.49%, and 73.13%; 90.98%, 74.10% and 64.57% in group 2 and 94.92%, 82.86% and 70.31% in group 3. Patient survival for 1, 5 and 12 years were 89.31%, 72.55% and 66.58% in group 1, 93.57%, 82.25% and 72.23% in group 2, and 92.62%, 79.76% and 66.79% in group 3. Acute rejections were noted in 16.6%, 15.8% and 17% respectively. CONCLUSIONS: In circumstances of organ shortage andunavailability of well developed ABO incompatible transplants, spousal donation is viable option.


Subject(s)
Kidney Transplantation/mortality , Living Donors/statistics & numerical data , Spouses/statistics & numerical data , Unrelated Donors/statistics & numerical data , Adult , Creatinine/blood , Female , Host vs Graft Reaction , Humans , India/epidemiology , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/surgery , Kidney Transplantation/methods , Kidney Transplantation/statistics & numerical data , Living Donors/classification , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Survival Analysis , Survival Rate , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...